INTRODUCTION: To develop and evaluate a technique of 3.0 Tesla magnetic resonance (MR) guided laser ablation based on 3-dimentional mapping biopsy (3DMB) for low risk prostate cancer. MATERIALS AND METHODS: The study was approved by the institutional review board and was the Health Insurance Portability and Accountability Act compliant. The prospective study was performed on seven 3DMB proven low risk prostate cancer patients. In the first phase of the procedure the patient's prostate was aligned to a position concordant with prior 3DMB using the transperineal grid and fiduciary golden marker coordinates. In the second phase ablation was performed using MR thermometry to determine the ablation endpoint and lesion coverage. Immediately after treatment dynamic contrast-enhanced MR imaging was done. Prostate-specific antigen testing was performed 3 and 12 months after the treatment and compared by ANOVA test. A follow up biopsy was done one year following ablation. RESULTS: The entire procedure took less than 2 hours and all patients tolerated the procedure well. There was a significant difference in prostate-specific antigen value before and 3 months after the treatment (p = 0.005). Four out of 6 patients had positive follow up biopsy for cancer. CONCLUSION: This study verifies the feasibility and safety of treating low risk prostate cancer with laser therapy guided by 3.0T MR imaging based on 3DMB.
INTRODUCTION: To develop and evaluate a technique of 3.0 Tesla magnetic resonance (MR) guided laser ablation based on 3-dimentional mapping biopsy (3DMB) for low risk prostate cancer. MATERIALS AND METHODS: The study was approved by the institutional review board and was the Health Insurance Portability and Accountability Act compliant. The prospective study was performed on seven 3DMB proven low risk prostate cancer patients. In the first phase of the procedure the patient's prostate was aligned to a position concordant with prior 3DMB using the transperineal grid and fiduciary golden marker coordinates. In the second phase ablation was performed using MR thermometry to determine the ablation endpoint and lesion coverage. Immediately after treatment dynamic contrast-enhanced MR imaging was done. Prostate-specific antigen testing was performed 3 and 12 months after the treatment and compared by ANOVA test. A follow up biopsy was done one year following ablation. RESULTS: The entire procedure took less than 2 hours and all patients tolerated the procedure well. There was a significant difference in prostate-specific antigen value before and 3 months after the treatment (p = 0.005). Four out of 6 patients had positive follow up biopsy for cancer. CONCLUSION: This study verifies the feasibility and safety of treating low risk prostate cancer with laser therapy guided by 3.0T MR imaging based on 3DMB.
Authors: R Jason Stafford; Anil Shetty; Andrew M Elliott; Sherry A Klumpp; Roger J McNichols; Ashok Gowda; John D Hazle; John F Ward Journal: J Urol Date: 2010-08-19 Impact factor: 7.450
Authors: Al B Barqawi; Kyle O Rove; Saeed Gholizadeh; Colin I O'Donnell; Hari Koul; E David Crawford Journal: J Urol Date: 2011-05-14 Impact factor: 7.450
Authors: Guillaume Ploussard; Jonathan I Epstein; Rodolfo Montironi; Peter R Carroll; Manfred Wirth; Marc-Oliver Grimm; Anders S Bjartell; Francesco Montorsi; Stephen J Freedland; Andreas Erbersdobler; Theodorus H van der Kwast Journal: Eur Urol Date: 2011-05-17 Impact factor: 20.096
Authors: Orit Raz; Masoom A Haider; Sean R H Davidson; Uri Lindner; Eugen Hlasny; Robert Weersink; Mark R Gertner; Walter Kucharczyk; Walter Kucharcyzk; Stuart A McCluskey; John Trachtenberg Journal: Eur Urol Date: 2010-03-12 Impact factor: 20.096
Authors: Jeri Kim; James Ebertowski; Matthew Janiga; Jorge Arzola; Gayle Gillespie; Michael Fountain; Douglas Soderdahl; Edith Canby-Hagino; Sally Elsamanoudi; Jennifer Gurski; John W Davis; Patricia A Parker; Douglas D Boyd Journal: BJU Int Date: 2013-01-25 Impact factor: 5.588
Authors: Al B Barqawi; Diliana Stoimenova; Kevin Krughoff; Khadijah Eid; Colin O'Donnell; Jason M Phillips; E David Crawford Journal: J Urol Date: 2014-03-15 Impact factor: 7.450
Authors: Hashim Uddin Ahmed; Yipeng Hu; Tim Carter; Nimalan Arumainayagam; Emilie Lecornet; Alex Freeman; David Hawkes; Dean C Barratt; Mark Emberton Journal: J Urol Date: 2011-06-15 Impact factor: 7.450
Authors: Ian A Donaldson; Roberto Alonzi; Dean Barratt; Eric Barret; Viktor Berge; Simon Bott; David Bottomley; Scott Eggener; Behfar Ehdaie; Mark Emberton; Richard Hindley; Tom Leslie; Alec Miners; Neil McCartan; Caroline M Moore; Peter Pinto; Thomas J Polascik; Lucy Simmons; Jan van der Meulen; Arnauld Villers; Sarah Willis; Hashim U Ahmed Journal: Eur Urol Date: 2014-10-01 Impact factor: 20.096